Penicillin (sometimes abbreviated PCN) refers to a group of β-lactam antibiotics used in the treatment of bacterial infections caused by susceptible, usually Gram-positive, organisms. The name “penicillin” can also be used in reference to a specific member of the penicillin group. Penicillins have the molecular formula R-C9H11N2O4S, where R is a variable side chain.
History
The serendipitous discovery of penicillin is usually attributed to Scottish scientist Alexander Fleming in 1928, though others had earlier noted the antibacterial effects of Penicillium. Fleming noticed a halo of inhibition of bacterial growth around a contaminant blue-green mould on a Staphylococcus plate culture. Fleming concluded that the mould was releasing a substance that was inhibiting bacterial growth and lysing the bacteria. He grew a pure culture of the mould and discovered that it was a Penicillium mould, now known to be Penicillium chrysogenum. Fleming coined the term "penicillin" to describe the filtrate of a broth culture of the Penicillium mould. Even in these early stages, penicillin was found to be most effective against Gram-positive bacteria, and ineffective against Gram-negative organisms and fungi. He expressed initial optimism that penicillin would be a useful disinfectant, being highly potent with minimal toxicity compared to antiseptics of the day, but particularly noted its laboratory value in the isolation of "Bacillus influenzae" (now Haemophilus influenzae).Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzæ. Br J Exp Pathol 1929;10(31):226–36. After further experiments, Fleming was convinced that penicillin could not last long enough in the human body to kill pathogenic bacteria and stopped studying penicillin after 1931, but restarted some clinical trials in 1934 and continued to try to get someone to purify it until 1940.
WL Issued to Amrex Zetron Inc FDA Tue, 14 Apr 2009 00:00:00 -0400 FDA Warning Letter Issued to Amrex Zetron Inc on 14 Apr 2009 by Los Angeles District Office WL Issued to Coast Institutional Review Board FDA Tue, 14 Apr 2009 00:00:00 -0400 FDA Warning Letter Issued to Coast Institutional Review Board on 14 Apr 2009 by Center for Drug Evaluation and Research WL Issued to Branitz, Bruce, MD FDA Thu, 09 Apr 2009 00:00:00 -0400 FDA Warning Letter Issued to Branitz, Bruce, MD on 09 Apr 2009 by Center for Drug Evaluation and Research WL Issued to Cote, Charles J., MD FDA Mon, 02 Mar 2009 00:00:00 -0400 FDA Warning Letter Issued to Cote, Charles J., MD on 02 Mar 2009 by Center for Drug Evaluation and Research WL Issued to Genzyme Corporation FDA Fri, 27 Feb 2009 00:00:00 -0400 FDA Warning Letter Issued to Genzyme Corporation on 27 Feb 2009 by New England District Office WL Issued to Hammill Manufacturing Company FDA Tue, 06 Jan 2009 00:00:00 -0400 FDA Warning Letter Issued to Hammill Manufacturing Company on 06 Jan 2009 by Cincinnati District Office
CFDA: FDA Latest Drug GCP Warning Letters
WL Issued to Coast Institutional Review Board FDA Tue, 14 Apr 2009 00:00:00 -0400 FDA Warning Letter Issued to Coast Institutional Review Board on 14 Apr 2009 by Center for Drug Evaluation and Research WL Issued to Branitz, Bruce, MD FDA Thu, 09 Apr 2009 00:00:00 -0400 FDA Warning Letter Issued to Branitz, Bruce, MD on 09 Apr 2009 by Center for Drug Evaluation and Research WL Issued to Bukowski, Ronald M, MD FDA Mon, 30 Mar 2009 00:00:00 -0400 FDA Warning Letter Issued to Bukowski, Ronald M, MD on 30 Mar 2009 by Center for Drug Evaluation and Research WL Issued to Youabian, Inc FDA Tue, 17 Mar 2009 00:00:00 -0400 FDA Warning Letter Issued to Youabian, Inc on 17 Mar 2009 by Los Angeles District Office WL Issued to Provena St. Joseph's Medical Center IRB FDA Thu, 12 Mar 2009 00:00:00 -0400 FDA Warning Letter Issued to Provena St. Joseph's Medical Center IRB on 12 Mar 2009 by Center for Biologics Evaluation and Research WL Issued to Paulson, Daniel M., MD FDA Wed, 11 Mar 2009 00:00:00 -0400 FDA Warning Letter Issued to Paulson, Daniel M., MD on 11 Mar 2009 by Center for Drug Evaluation and Research